Sources agree on the Seed stage, $5.4 million amount, September 24, 2026 announcement date, ACE Ventures as lead, and GoHub Ventures and SICTIC as participating investors. The release also mentions “prominent angel investors,” but does not name them, so they are not listed.
[ BUILT WITH ]·[ SEARCH ]found by corroboration·[ SCRAPE ]6 pages read: aceandcompany.com, capital-riesgo.es, previsionmedicine.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]correctedread back across 6 sources·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]dossier built by the Firecrawl agent
Sources agree on the Seed stage, $5.4 million amount, September 24, 2026 announcement date, ACE Ventures as lead, and GoHub Ventures and SICTIC as participating investors. The release also mentions “prominent angel investors,” but does not name them, so they are not listed.
[ BUILT WITH ]·[ SEARCH ]found by corroboration
Dossier
[ CHECKED ]
Fetched today
Prevision Medicine tests a patient's own living cancer cells against 100+ drugs and combinations to help physicians make more informed treatment decisions.
He originally joined Berend Snijder’s group as its first PhD student and helped build the Zurich lab from the ground up.
Valentin Matillon · Chief Business Officer (CBO) & Co-Founder
He has more than 25 years of experience in senior financial-management positions and more than a decade in the startup ecosystem focused on scaling biotech companies.
Philip Zimmermann · Chief Executive Officer (CEO) & Co-Founder
He has a deep history in precision medicine and bioinformatics and holds a PhD in Life Sciences from ETH Zurich.
Berend Snijder · Scientific Co-Founder and Chairman of the Board
He is a faculty member at the Botnar Institute of Immune Engineering, a group leader at the Swiss Institute of Bioinformatics and the Comprehensive Cancer Center Zurich, a former Assistant Professor at ETH Zurich, and a co-founder of Allcyte and Graph Therapeutics.